Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (744)	2/12/2003 11:54:42 PM
From: Miljenko Zuanic	Respond to of 3557

That Kineret and Enbred do not synergy well is known from last RA conference. It is like double taxation. BTW, oral Axokine is for now on hold. This was difficult task from start, time-controlled release formulation. Miljenko

To: keokalani'nui who wrote (744)	2/17/2003 7:04:35 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 3557

Interesting for IL-1 Trap, as it's action more effectively neutralize IL-1 (IL-1a and IL-1b). asco.org IL-1 receptor antagonist prevents tumor angiogenesis in animal model Anakinra is approved by the US Food and Drug Administration for reducing inflammation in patients with rheumatoid arthritis (see Reuters Health report, April 11, 2002, "Addition of anakinra offers option for methotrexate-refractory rheumatoid arthritis"). Previous studies have also demonstrated the ability of IL-1 to promote tumor invasion. Dr. Ron N. Apte, of Ben-Gurion University of the Negev in Beer-Sheva, Israel, and colleagues compared tumor growth and angiogenesis in wild-type and IL-1 knockout mice, and report their findings in the February 18th early edition of the Proceedings of the National Academy of Sciences. After intravenous injection of melanoma cells, all 10 wild-type mice died within 20 days due to lung metastasis, while 10 similarly treated IL-1-beta knockout mice survived. Injection of the cells into their footpads was followed by progressive tumor growth in normal mice but no tumor development in the knockout mice. Angiogenic responses were also prevented in the knockout mice. Repeat studies with IL-1-alpha knockout mice showed a response intermediate between that observed in wild type and the IL-1-beta knockouts. However, in similar studies with mammary cancer tumors, the authors observed that IL-1-alpha played a more dominant role than did IL-1-B. IL-1Ra added to melanoma cell implants in wild-type mice "significantly reduced the outgrowth of tumors and the recruitment of an angiogenic network," the scientists add. "Blockade of a single molecule, i.e., IL-1, may inhibit the cascade of downstream (effector) angiogenic factors," such as vascular endothelial cell growth factor, tumor necrosis factor-alpha, and IL-6, the authors propose. Proc Natl Acad Sci 2003. www.pnas.org/cgi/doi/10.1073/pnas.0437939100